General
Preferred name
ZOTEPINE
Synonyms
Orion brand of zotepine ()
Zoleptil 50 ()
Nipolept ()
Zoleptil 100 ()
Setous ()
Zotepin ()
Zoleptil 25 ()
P&D ID
PD008996
CAS
26615-21-4
1200591-33-8
Tags
available
drug
Drug Status
investigational
approved
withdrawn
Drug indication
Anxiety disorder
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Zotepine, like other atypical antipsychotics, is considered as the first-line treatment in newly diagnosed schizophrenia. It is usually thought to be an option of choice for managing acute schizophrenic episodes when discussion with the patient is not possible. Zotepine, as an atypical antipsychotic, is used in patients who are suffering unacceptable side effects from conventional antipsychotics or in relapse patients that were inadequately controlled.[T108] ; ; It is important to consider that the indications stated above are related to atypical antipsychotics, that zotepine is not currently FDA, Canada or EMA approved and that studies have not shown any additional benefit when compared with other approved atypical antipsychotics.[A31857]; ; Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves. It is usually marked for a loose reality perspective delineated by hallucinations, delusions and thought and movement disorders.[L1320]
DESCRIPTION
Zotepine is an atypical antipsychotic drug, with antagonist activity at dopamine and serotonin receptors.
(GtoPdb)
DESCRIPTION
Zotepine is a 5-HT2A receptor and dopamine D2 receptor antagonist (Ki = 0.69 and 2.3 nM, respectively) used as an atypical antipsychotic for the treatment of schizophrenia. Zotepine also exhibits an antagonistic effect at histamine H1 receptor (IC50 = 8.0 nM).
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
19
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
32
Molecular Weight
331.08
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
2
cLogP
4.88
TPSA
12.47
Fraction CSP3
0.22
Chiral centers
0.0
Largest ring
7.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
member
MOA
Adrenergic receptor modulator
Dopamine D2 Antagonists
Serotonin Antagonists
dopamine receptor antagonist, serotonin receptor antagonist
Indication
schizophrenia
Target
ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4
5-HT Receptor
Adrenergic Receptor
Dopamine Receptor
Histamine Receptor
Pathway
GPCR/G protein
Immunology/Inflammation
Neuronal Signaling
Source data
